- Home
- WRD vs OGN Comparison
WRD vs OGN Comparison
Compare WRD & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRD
- OGN
- Stock Information
- Founded
- WRD 2017
- OGN 1923
- Country
- WRD China
- OGN United States
- Employees
- WRD N/A
- OGN N/A
- Industry
- WRD
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- WRD
- OGN Health Care
- Exchange
- WRD NYSE
- OGN Nasdaq
- Market Cap
- WRD 4.8B
- OGN 4.0B
- IPO Year
- WRD 2024
- OGN N/A
- Fundamental
- Price
- WRD $15.66
- OGN $14.77
- Analyst Decision
- WRD Buy
- OGN Hold
- Analyst Count
- WRD 1
- OGN 3
- Target Price
- WRD $23.00
- OGN $21.33
- AVG Volume (30 Days)
- WRD 114.2K
- OGN 2.9M
- Earning Date
- WRD 12-24-2024
- OGN 02-13-2025
- Dividend Yield
- WRD N/A
- OGN 7.65%
- EPS Growth
- WRD N/A
- OGN 120.97
- EPS
- WRD N/A
- OGN 5.04
- Revenue
- WRD $52,046,475.00
- OGN $6,409,000,000.00
- Revenue This Year
- WRD N/A
- OGN $3.11
- Revenue Next Year
- WRD N/A
- OGN $2.55
- P/E Ratio
- WRD N/A
- OGN $2.93
- Revenue Growth
- WRD N/A
- OGN 4.21
- 52 Week Low
- WRD $14.10
- OGN $13.14
- 52 Week High
- WRD $22.69
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- WRD N/A
- OGN 38.85
- Support Level
- WRD N/A
- OGN $14.80
- Resistance Level
- WRD N/A
- OGN $15.41
- Average True Range (ATR)
- WRD 0.00
- OGN 0.52
- MACD
- WRD 0.00
- OGN 0.01
- Stochastic Oscillator
- WRD 0.00
- OGN 14.75
About WRD WERIDE INC. SPON ADS EACH REP 3 CL A ORD SHS
WeRide Inc operates in the autonomous driving industry. The company has developed a universal autonomous driving technology platform that integrates full-stack software algorithms, modularized hardware solutions, and a cloud-based infrastructure platform. The company provides autonomous driving products and services from L2 to L4 vehicles. The products of the company includes Robotaxi, Robobus, Robovan, Robosweeper, and others. The company earns its revenue from the People's Republic of China.
About OGN Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.